Heptyl-(4-methyl-benzyl)-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Heptyl-(4-methyl-benzyl)-amine
• 英文别名: P-Methylbenzyl-heptylamine；N-[(4-methylphenyl)methyl]heptan-1-amine
• 化学式: C₁₅H₂₅N
• mdl: MFCD03210671
• 分子量: 219.37
• InChiKey: RDMOZWNRZMHRTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  16
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  庚胺 、 对甲苯腈 在 nickel(II) triflate 、 氢气 、 双(2-二苯基膦乙基)苯基磷 作用下， 以 2,2,2-三氟乙醇 为溶剂， 100.0 ℃ 、4.0 MPa 条件下， 反应 16.0h， 以90%的产率得到Heptyl-(4-methyl-benzyl)-amine
  参考文献：
  名称：

  镍催化腈和胺的氢化偶联用于一般胺合成

  摘要：

  合成胺的有效和通用方法在化学工业中仍然有很高的需求。在许多已知的方法中，催化加氢是一种经济有效且经工业验证的反应，目前用于生产多种此类化合物。我们报告了一种均相镍催化剂，用于将一系列芳族、杂芳族和脂肪族腈与伯胺和仲胺或氨进行氢化交叉偶联。该通用氢化方案通过直接和高选择性合成 > 230 种功能化和结构多样的胺（包括药学相关和手性产物）以及15N-同位素标记应用。

  DOI：

  10.1126/science.abn7565

文献信息

• Compounds useful for the treatment of degenerative and inflammatory diseases
  申请人：GALAPAGOS NV

  公开号：US10206907B2

  公开（公告）日：2019-02-19

  [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g. diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection) and proliferative diseases.

  所公开的[1,2,4]三唑并[1,5-a]吡啶化合物具有下式： 这些化合物可制备成药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，包括非限制性实例，涉及软骨退化、骨和/或关节退化的疾病，例如骨关节炎；和/或涉及炎症或免疫反应的疾病，例如克罗恩病、类风湿性关节炎、银屑病、过敏性气道疾病（如哮喘、鼻炎、幼年特发性关节炎、荨麻疹等）。哮喘、鼻炎）、幼年特发性关节炎、结肠炎、肠道炎症性疾病、内毒素驱动的疾病状态（如搭桥手术后的并发症或导致慢性心力衰竭等的慢性内毒素状态）、涉及软骨代谢损伤的疾病（如涉及合成代谢疾病的疾病）、涉及骨质疏松症的疾病（如骨质疏松症）、涉及骨质疏松症的疾病（如骨质疏松症）、涉及骨质疏松症的疾病（如骨质疏松症）。先天性软骨畸形、与 IL6 分泌过多和移植排斥有关的疾病（如器官移植排斥）以及增殖性疾病。
• NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
  申请人：MENET Christel Jeanne Marie

  公开号：US20170035738A1

  公开（公告）日：2017-02-09

  [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g. diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection) and proliferative diseases.